Your not really telling us that this in any way shape or form that this is to be compared to Dendreon? I played that and I am astutely aware that there were far and diverse and bigger dynamics at play than those projections. An Bio tech company in no way should be brought up as a comparison to a solar company. As for SLMU projections....unless you're an insider and knowledgeable of all insider dynamics and contracts you can't say that either. IMO...very irresponsible to think this should be a issue.
Herein lies the challenge for a management used to working in the OTC world in terms of how it operates in the NASDAQ sphere.
The same thing was seen at the Sunlogics Inc where I worked, where they regularly flaunted numbers of hundreds of millions of dollars in year two, and we all know how that worked out. I think they are just hitting $4M with no profits to speak of.
So I totally agree that for management to remain credible, they'll have to shed some old habits. Time will tell if they can do it or not.